 |
Vol.46 No.1 contents | Japanese/English |
 | Full Text of PDF (419K) Article in Japanese |
- Case Report -
TS-1 Response to Postoperative Recurrence of Non-small Cell Lung Cancer in a Patient Resistant to Gefitinib
Masayoshi Inoue1, Masato Minami1, Hiroyuki Shiono1, Noriyoshi Sawabata1, Meinoshin Okumura11Division of General Thoracic Surgery, Department of Surgery (E1), Osaka University Graduate School of Medicine, Japan
Background. The efficacy of TS-1 as second line therapy for lung cancer is still obscure. We report our clinical experience with TS-1 administered in an elderly patient with relapsing pulmonary adenocarcinoma resistant to gefitinib. Case. A 78-year old woman had a good partial response to treatment with gefitinib for recurrence of an adenocarcinoma at the surgical margin following partial resection of the right lower lobe. Since tumor recurrence on the surgical margin occurred despite gefitinib administration, we gave 3 courses of oral chemotherapy using TS-1 at 100 mg/day (75 mg/m2/day) for 28 days, followed by withdrawal for 14 days, on an outpatient basis. Chest computed tomography showed a partial response, with a size reduction of 61%, while the serum level of the carcinoembryonic antigen decreased from 16 ng/ml to 8 ng/ml. With this TS-1 regimen, patient quality of life was preserved, though Grade 1 anorexia and bilirubinemia were observed. Conclusion. TS-1 could be an option for second line treatment for recurrent non-small cell lung cancer.
key words: S-1, Lung cancer, Recurrence, Chemotherapy, Gefitinib
Received: October 20, 2005
Accepted: December 7, 2005
JJLC 46 (1): 41-44, 2006
